{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:39:42Z","timestamp":1790631582204,"version":"4.1.0"},"reference-count":9,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2025,5,31]]},"DOI":"10.5582\/irdr.2025.01010","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T22:12:45Z","timestamp":1741385565000},"page":"143-144","source":"Crossref","is-referenced-by-count":9,"title":["Vimseltinib: A novel colony stimulating factor 1 receptor (CSF1R) inhibitor approved for treatment of tenosynovial giant cell tumors (TGCTs)"],"prefix":"10.5582","volume":"14","author":[{"given":"Fangzhou","family":"Dou","sequence":"first","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoran","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Benner B, Good L, Quiroga D, Schultz TE, Kassem M, Carson WE, Cherian MA, Sardesai S, Wesolowski R. Pexidartinib, a novel small molecule CSF-1R inhibitor in use for tenosynovial giant cell tumor: A systematic review of pre-clinical and clinical development. Drug Des Devel Ther. 2020; 14:1693-1704.","DOI":"10.2147\/DDDT.S253232"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ehrenstein V, Andersen SL, Qazi I, Sankar N, Pedersen AB, Sikorski R, Acquavella JF. Tenosynovial giant cell tumor: Incidence, prevalence, patient characteristics, and recurrence. A registry-based cohort study in Denmark. J Rheumatol. 2017; 44:1476-1483.","DOI":"10.3899\/jrheum.160816"},{"key":"3","unstructured":"3. National Organization for Rare Disorders. Tenosynovial giant cell tumor. <i>https:\/\/rarediseases.org\/rare-diseases\/tenosynovial-giant-cell-tumor\/#affected<\/i> (accessed February 21, 2025)."},{"key":"4","unstructured":"4. US Food and Drug Administration. FDA approves vimseltinib for symptomatic tenosynovial giant cell tumor. <i>https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-vimseltinib-symptomatic-tenosynovial-giant-cell-tumor<\/i> (accessed February 23, 2025)."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. van IDGP, Matusiak M, Charville GW, <i>et al<\/i>. Interactions in CSF1-driven tenosynovial giant cell tumors. Clin Cancer Res. 2022; 28:4934-4946.","DOI":"10.1158\/1078-0432.CCR-22-1898"},{"key":"6","unstructured":"6. US Food and Drug Administration. FDA approves pexidartinib for tenosynovial giant cell tumor. <i>https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pexidartinib-tenosynovial-giant-cell-tumor<\/i> (accessed February 28, 2025)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Caldwell TM, Ahn YM, Bulfer SL, Leary CB, Hood MM, Lu WP, Vogeti L, Vogeti S, Kaufman MD, Wise SC, Le Bourdonnec B, Smith BD, Flynn DL. Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT). Bioorg Med Chem Lett. 2022; 74:128928.","DOI":"10.1016\/j.bmcl.2022.128928"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Gelderblom H, Bhadri V, Stacchiotti S, <i>et al<\/i>. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024; 403:2709-2719.","DOI":"10.1016\/S0140-6736(24)00885-7"},{"key":"9","unstructured":"9. Abbisko News. Abbisko therapeutics obtained approval from U.S. FDA for pivotal global multi-center phase III clinical trial of CSF-1R inhibitor pimicotinib (ABSK021). <i>https:\/\/www.abbisko.com\/newsDetail\/135.html<\/i> (accessed February 28, 2025)."}],"container-title":["Intractable &amp; Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/14\/2\/14_2025.01010\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T04:28:27Z","timestamp":1749875307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/14\/2\/14_2025.01010\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2025.01010","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"article-number":"2025.01010"}}